Document:

exv10w5w3

 

[Incyte Company Logo]

Exhibit 10.5.3

*** Confidential Treatment Requested. Confidential portions of this document have been redacted

and have been separately filed with the Commission.

July 19, 2002

Genomic Health, Inc.

301 Penobscot Drive

Redwood City, CA 94063

	 	 	 
	Attn:

	 	Randy Scott
	

	 	Chief Executive Officer

Re: Collaborative Agreement between Genomic Health, Inc. (“GHI”) and Incyte Genomics, Inc.
(“Incyte”)

Dear Randy:

     On March 30, 2001, GHI and Incyte entered into a Collaborative Agreement (the “Original
Agreement”); and on December 21, 2001, GHI and Incyte amended the Original Agreement.

     This letter amendment (“Second Amendment”) when signed on behalf of GHI as of the date
hereof shall further amend the terms of the Original Agreement.

     Except as expressly set forth in this Second Amendment all capitalized terms used herein shall
have the meanings set forth in the Original Agreement.

     THEREFORE, GHI and Incyte agree to amend Section 4.1 of the Original Agreement as
set forth below.

1. Deferral

     As further set forth in the schedule attached hereto as Exhibit A, GHI shall defer
payment of *** Dollars (US $***) of the *** Dollars (US $***) in Access Fee(s) due Incyte during
the 2002 calendar year per Section 4.1. Such deferred amount shall be deferred by GHI on a
quarterly basis; accordingly, subject to the terms set forth below, GHI shall pay Incyte ***
Dollars (US $***) less per quarter than originally owed Incyte in 2002 under the Original
Agreement.

2. Interest

     The deferred *** Dollars (US $***) shall accrue interest at a fixed rate of *** percent
(***%), which equals a total sum of *** Dollars (US $***) upon completion of timely repayment.

 

 

[Incyte Company Logo]

*** Confidential material redacted and filed separately with the Commission.

     3. Repayment

     In addition to the Access Fees of *** Dollars (US $***) due Incyte during the 2003 and 2004
calendar years, GHI shall pay Incyte *** Dollars (US $***) per quarter (starting Q1, 2003) towards
repayment of the deferred amount plus accrued interest.

     Except as expressly amended hereby, all other terms of the Original Agreement shall remain in
full force and effect. This Second Amendment may be executed in counterparts, each of which shall
be an original, but such counterparts shall together constitute but one and the same document.

     IN WITNESS THEREOF, the parties hereto have caused this Second Amendment to be executed in
duplicate by their duly authorized representatives.

	 	 	 	 	 	 	 	 	 
	INCYTE GENOMICS, INC.	 	 	 	GENOMIC HEALTH, INC.
	 
	 	 	 	 	 	 	 	 
	Signed:

	 	/s/ James Merryweather
	 	 	 	Signed:
	 	/s/ Randy Scott
	

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	James Merryweather, Ph.D.	 	 	 	Name:	 	Randy Scott
	 
	 	 	 	 	 	 	 	 
	Executive Vice President, Business Development	 	 	 	Title:	 	CEO
	and Commercial Operations	 	 	 	 	 	 

 

 

[Incyte Company Logo]

Exhibit A

Deferral, Interest and Repayment Schedule

 

 

*** Confidential material redacted and filed separately with the Commission.

GHI — Incyte Payment Deferral Note

	 	 	 	 	 	 	 	 	 
	Interest
	 	 	 	 	 	 	 	 
	Prime
	 	 	***	%	 	 	 	 
	Spread
	 	 	***	%	 	 	 	 
	 
	 	 	 	 	 	 	 
	Total
	 	 	***	%	 	Fixed Rate for Duration of Deferral

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Beginning	 	 	 	 	 	 	 	 	 	 	Principal	 	 	 	 	 	 	 	 	 	 	 	 
	Period	 	Balance	 	 	Payment	 	 	Interest	 	 	Amortization	 	 	Ending Balance	 	 	 	 	 	 	 	 	 
	 
	1-Jan-2002
	 	 	—	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Feb-2002
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Mar-2002
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Apr-2002
	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-May-2002
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Jun-2002
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Jul-2002
	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Aug-2002
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Sep-2002
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Oct-2002
	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Nov-2002
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	***	 	 	 	 
	1-Dec-2002
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	*	**
	1-Jan-2003
	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	***	 	 	 	 
	1-Feb-2003
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	*	**
	1-Mar-2003
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Apr-2003
	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-May-2003
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Jun-2003
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Jul-2003
	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Aug-2003
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Sep-2003
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Oct-2003
	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Nov-2003
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	***	 	 	 	 
	1-Dec-2003
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	*	**
	1-Jan-2004
	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	***	 	 	 	 
	1-Feb-2004
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	*	**
	1-Mar-2004
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Apr-2004
	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-May-2004
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Jun-2004
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Jul-2004
	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Aug-2004
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Sep-2004
	 	 	*	**	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Oct-2004
	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 
	1-Nov-2004
	 	 	*	**	 	 	—	 	 	 	 	 	 	 	 	 	 	 	*	**	 	***	 	 	 	 
	1-Dec-2004
	 	 	*	**	 	 	—	 	 	 	 	 	 	 	 	 	 	 	*	**	 	 	 	 	 	 	*	**
	1-Jan-2005
	 	 	*	**	 	 	—	 	 	 	—	 	 	 	 	 	 	 	*	**	 	***	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	*	**
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Totals
	 	 	 	 	 	 	*	**	 	 	*	**	 	 	*	**	 	 	 	 	 	 	 	 	 	 	*	**exv10w5w4

 

Exhibit 10.5.4

*** Confidential Treatment Requested. Confidential portions of this document have been redacted

and have been separately filed with the Commission.

Amendment #3 to LifeSeq® Collaborative Agreement

     This Amendment to the LifeSeq® Collaborative Agreement (this “Amendment”)
is entered into as of October 25,2004 (the “Amendment Effective Date”) by and between
Incyte Corporation (f/k/a Incyte Genomics, Inc.), a Delaware Corporation (“Incyte”) and
Genomic Health, Inc., a Delaware corporation (“GHI”).

Recitals

     WHEREAS, Incyte and GHI are parties to the LifeSeq® Collaborative Agreement between
Incyte Genomics, Inc. and Genomic Health, Inc. dated March 30,2001 (the “Agreement”) as
amended December 21,2001 and further amended on July 19,2002; and

     WHEREAS, Incyte and GHI desire to amend and supplement of the Agreement as set forth below.

     NOW, THEREFORE, in consideration of the premises and the mutual agreements and covenants set
forth herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the parties agree as follows:

Amendment as of the Amendment Effective Date

     1. The definition of “Access Term‘?in Article 1.0 of the Agreement is hereby deleted
and replaced with the following:

“Access Term” shall mean the period commencing on the Effective Date and
continuing in perpetuity, unless the Agreement is earlier terminated pursuant to
Article 7.0.

     2. The definition of “Designated Gene” in Article 1.0 of the Agreement is hereby
deleted in its entirety and Incyte and GHI hereby agree to the following procedure for
identification of a “Designated Gene”:

	 	(a)  	In the event GHI desires to acquire a nonexclusive license in
respect of a GenelGene Derivative that has been Used by GHI, in accordance with
Article 3 of the Agreement, during the License Term GHI shall make a written
request to Incyte identifying such Gene/Gene Derivative.
	 
	 	(b)  	Incyte shall, within thirty (30) days, from the date of receipt
of such written request respond to GHI and advise whether or not GHI may
acquire a
nonexclusive license in respect of such Gene/Gene Derivative. Incyte may only
advise GHI that it may not acquire a non-exclusive license in respect
of such Gene/Gene Derivative if (i) Incyte has already exclusively licensed such
Gene/Gene Derivative to another, or (ii) Incyte has committed to exclusively
license such Gene/Gene Derivative to another, or (iii) Incyte is in bona fide
negotiations with another to exclusively license such Gene/Gene Derivative.

1

 

*** Confidential material redacted and filed separately with the Commission.

	 	(c)  	GHI shall have fifteen (15) days from the date of
receipt of Incyte’s response that such Gene/Gene Derivative is available for
licensing to respond in writing that it wants to acquire a nonexclusive license
in respect of such Gene/Gene Derivative. Upon Incyte’s receipt of such
response, the specified Gene/Gene Derivative shall be deemed a “Designated
Gene.”

     3. All references to the term “Designated Gene/Gene Derivative” throughout the Agreement are
hereby replaced with the term “Designated Gene.”

     4. The definition of “LifeSeq® Gold Database” in Article 1.0 and the
corresponding Exhibit A are hereby deleted in their entirety.

     5. The definition of “LifeSeq® Database Product(s)” in Article 1.0 is
hereby deleted and replaced with the following:

“LifeSeq® Database Products” shall mean the March 2004 release of
Incyte’s proprietary database of Database Information, any LifeSeq®
Database Products previously provided to GHI, and the December 2003 release of
Incyte’s database of expressed sequence tags from rat, mouse, monkey and dog,
including any gene assemblies with any derived tissue specific expression
information, and referred to as ZooSeq®, all as provided to GHI.

     6.       The following definition is hereby added to Article 1.0 of the Agreement:

“License Term” shall mean three years beginning on the Amendment Effective
Date unless earlier terminated pursuant to Article 7.0 or extended pursuant to
Section 7.2.

     7.       The definition of “Net Sales” in Article 1.0 is hereby deleted and replaced with
the following:

“Net Sales”: shall mean:

with respect to Products that are provided as products, invoiced sales by GHI, GHI
Affiliates or sublicensees on all sales of Product (in final form for end use) to an
unaffiliated third party (whether an end-user, a distributor or otherwise), and
exclusive of intercompany transfers or sales, less the following deductions from
such invoiced sales which are actually incurred, to the extent that they are
reasonable and customary, and to the extent that they do not exceed *** percent
(***%) of invoiced sales in a calendar quarter:

	 	a)  	credits or allowances actually granted for damaged Products,
returns or rejections of Product and retroactive price reductions;
	 
	 	b)  	freight, postage, shipping, customs duties and insurance
charges;
	 
	 	c)  	normal and customary trade, cash and quantity discounts,
allowances and credits;

2

 

*** Confidential material redacted and filed separately with the Commission.

	 	d)  	uncollected amounts to the extent not exceeding *** percent (***%) of
invoiced sales for a calendar quarter; and
	 
	 	e)  	sales, value added or similar taxes measured by the billing
amount, when included in billing.

with respect to Products that are provided as services, the gross invoice price for
such services performed by GHI, less the following deductions where they are
factually applicable and are not already reflected in the gross invoice price:

	 	a)  	discounts allowed and taken, in amounts customary in the trade
(which shall include the difference between the dollar amount charged by GHI
for a Licensed Service and the Medicare and/or Medicaid Limits of Allowance
and/or reimbursement limitations of a Third Party insurance program, each to
the extent specifically applicable to a particular sale, and only if no payment
beyond such limits is received by GHI in any form for such service); and
	 
	 	b)  	actual bad debt, calculated in accordance with GAAP, not
exceeding ***% of gross invoice price for such services, provided that such
***% limitation shall not apply in the event that GHI can demonstrate by
reasonably satisfactory evidence that it was reasonable and diligent in its
debt collection practices.

     8. Section 2.1.3 of the Agreement is hereby deleted and replaced with the following:

2.1.3 No Updated Releases or Updates. Notwithstanding anything in this
Agreement to the contrary, Incyte shall have no obligation to provide GHI with any
updates to, updated releases of or support to the LifeSeq® Database
Products.

     9. In Section 2.3.4 of the Agreement, the term “Access Term” is hereby replaced with the term
“License Term.”

     10. Section 2.3.7 of the Agreement is hereby deleted and replaced with the following:

2.3.7 Termination of Access Term and/or License Term. Upon any
termination of the Access Term, GHI shall discontinue use of all LifeSeq Database
Products and Database Information and remove each LifeSeq® Database
Product(s) from each Installation Site(s), and promptly return to Incyte, or upon
Incyte’s written instruction, destroy all portions and copies of LifeSeq®
Database Products and the Database Information. Upon expiration or termination of
the License Term, GHI
shall perform with Incyte a mutually acceptable final accounting of those Designated
Genes which are subject to one or more of the licenses granted to GHI under Article
3 below.

     11. Section 3.1.2 is hereby deleted in its entirety.

     12. Section 3.3 is hereby deleted in its entirety.

3

 

*** Confidential material redacted and filed separately with the Commission.

     13. Incyte and GHI hereby agree that within thirty (30) days after the Amendment
Effective Date, GHI shall pay to Incyte $*** and upon Incyte’s receipt of such payment, GHI shall
have no further obligation to make any payments to Incyte under Section 4.1 of the Agreement.

     14. Note (d) below Table 4.2 is hereby deleted.

     15. The first paragraph of Section 4.3 is hereby deleted and replaced with the following:

The foregoing payments under Section 4.2 will accrue or become due or payable with respect to
Product(s) which are covered by a Valid Claim of Incyte Patent Rights and/or to Products which are
identified or discovered by a process which (i) utilizes a Gene which is covered by a Valid Claim
of Incyte Patent Rights and (ii) where the use of such Gene for such identification or discovery
would have constituted an infringement of Incyte Patent Rights but for licenses granted hereunder.

     16. The first sentence of Section 4.5 “Mode of Payment” is hereby deleted and replaced with
the following:

For the purposes of determining when a sale of a royalty-bearingProduct occurs, the sale shall be
deemed to occur on the date that revenue resulting from such sale is recorded on GHI books in
accordance with Generally Accepted Accounting Principles.

     17. GHI acknowledges that Incyte has delivered to GHI as part of the LifeSeq®
Database Product, a version of SRS Runtime (“SRS") developed by LION bioscience,
Inc. which may be used by GHI in connection with the LifeSeq® Database Products by
entering into an agreement with LION bioscience, Inc. GHI shall have no obligation to use SRS. GHI
shall have the option to use the LifeSeq® Database Product in flat file format at GHI’s
sole discretion. If GHI does not use SRS, GHI shall have no obligation to enter into an agreement
with LION bioscience, Inc. with regard to the use of SRS.

     18. Incyte and GHI hereby agree that notwithstanding anything in the Agreement to the
contrary, GHI shall have no access to LifeSeq® Database Products via the Internet and
Incyte shall have no obligation to provide such.

     19. Article 7.0 (including Sections 7.1, 7.2, 7.4 and 7.5) is hereby deleted and replaced with
the following:

7.0 TERM; TERMINATION.

	 	7.1  	Termination of Agreement. This Agreement shall continue
in perpetuity unless earlier terminated in accordance with Section 7.4. Upon
any such termination of this Agreement, the License Term and Access Term shall
also be terminated as of the date of termination of this Agreement.
	 
	 	7.2  	Extension of License Term. During the term of this Agreement,
GHI shall have the right to extend the License Term for additional one-year
terms by

4

 

*** Confidential material redacted and filed separately with the Commission.

	 	   	(i) providing written notice to Incyte at least ninety (90)
days prior to the end of the then current License Term and (ii) payment to
Incyte of a License Term Extension Fee of US$*** at least thirty (30) days
prior to the end of the then current License Term. For the avoidance of
doubt, the License Term Extension Fee is an annual fee that shall be due to
Incyte for each year that GHI desires to extend the initial three-year
License Term.

	 	7.3  	Maintenance of Licenses. Effective on the one year
anniversary of the expiration of the License Term (“Maintenance Fee
Date”), to retain any license procured under Sections 3.1 and 3.2
inclusive, GHI shall on a Designated Gene by Designated Gene basis, pay to
Incyte a non-refundable Annual License Maintenance Fee. The Annual License
Maintenance Fee is *** Dollars (US$***) per year per Designated Gene. The
Annual License Maintenance Fee shall be paid to Incyte at least thirty (30)
days prior to the anniversary of the Maintenance Fee Date until:

	 	(a)  	GHI has developed a Product for
which a milestone payment has been made to Incyte pursuant to
Article 4.0 in which case such license shall then be in effect
in perpetuity; or
	 
	 	(b)  	GHI no longer desires to retain
such license in which case (i) GHI shall provide written
notification to Incyte and the Escrow Agent of such desire; (ii)
GHI shall not be obligated to pay any more Annual License
Maintenance Fees in respect of the license for the Designated
Gene; and (iii) such license shall be terminated.

	 	7.4  	Breach. Material failure by either Party to comply with
any of its obligations under this Agreement shall entitle the other Party to
give to the Party in default notice specifying the nature of the default and
requiring it to cure such default. If such default is not cured within ninety
(90) days after the receipt of such notice, the notifying Party shall be
entitled, without prejudice to any of its other rights conferred on it by this
Agreement, in addition to any other remedies available to it by law or in
equity, immediately to terminate this Agreement by giving notice to the other
Party. The right of a Party to terminate this Agreement, as hereinafter
provided, shall not be affected in any way by its waiver or failure to take
action with respect to any previous default.
	 
	 	7.5  	Accrued Rights Surviving Obligations. Termination,
relinquishment or expiration of this Agreement for any reason shall be without
prejudice to any rights which shall have accrued to the benefit of either Party
prior to such termination, or expiration. Upon any termination, relinquishment
or expiration of this Agreement, the following provisions will not terminate,
but will continue in full force and effect: Section 2.3.7 and Articles 5

5

 

	 	   	(Confidentiality),6 (IntellectualProperty), 7 (Term), 8
(Representations/Warranties), 9 (Indemnity), and 10 (Miscellaneous), and any
licenses under Article 3 which have become perpetual pursuant to Sections
4.4 or 7.3 and any corresponding payment obligations and terms under Article
4.

	 	20.  	Section 10.7 is hereby amended to update the address of Incyte as follows:

	 	 	 	 	 
	 

	 	Incyte Corporation

Experimental Station
E336

Route 141 and Henry Clay Boulevard

Wilmington, Delaware 19880

Attn: General Counsel

Fax: 302-425-2722
	 	 

     21. Except as specifically modified or amended by this Amendment which Amendment is effective
as of Amendment Effective Date, the Agreement shall remain in full force and effect. For purposes
of clarity, this Amendment is not retroactive, therefore as of prior to the Amendment Effective
Date, the Agreement shall remain in full force and effect as it existed prior to this Amendment.

     IN WITNESS WHEREOF, Incyte and GHI have caused this Amendment to be executed by their
respective duly authorized officers as of the Amendment Effective Date.

	 	 	 	 	 	 	 	 	 
	Incyte Corporation	 	 	 	Genomic Health, Inc.
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ John Keller
	 	 	 	By:
	 	/s/ Randy Scott
	

	 	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Name:

	 	John Keller
	 	 	 	Name:
	 	Randy Scott
	 
	 	 	 	 	 	 	 	 
	Title:

	 	EVP & CBO
	 	 	 	Title:
	 	CEO

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]